What is Syllable?
Headquartered in San Jose, California, Syllable operates at the intersection of healthcare services and artificial intelligence. The company specializes in developing sophisticated voice and web-based assistants designed to streamline the complex interactions between patients and hospital systems. By automating administrative workflows and enhancing accessibility, Syllable addresses critical inefficiencies in healthcare delivery. Their platform serves as a digital bridge, ensuring that patients receive timely information while reducing the operational burden on clinical staff. This focus on scalable, AI-driven infrastructure has positioned the company as a vital partner for healthcare organizations seeking to improve patient engagement and operational throughput in an increasingly digital-first environment.
How much funding has Syllable raised?
Syllable has raised a total of $81.7M across 3 funding rounds:
Series A
$13.7M
Series B
$28M
Series C
$40M
Series A (2018): $13.7M, investors not publicly disclosed
Series B (2021): $28M led by Section 32 and Oak HC/FT
Series C (2022): $40M supported by Section 32, Verily, Oak HC/FT, and The TCV
Key Investors in Syllable
Section 32
S32 is a venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and visionary entrepreneurs at the forefront of technological advancement.
Oak HC/FT
Oak HC/FT is a premier venture growth-equity fund specializing in healthcare information and services, providing strategic counsel and extensive industry network access to its portfolio companies.
Verily
A subsidiary of Alphabet Inc., Verily is a healthcare technology company focused on improving health outcomes through data-driven research, analytics tools, and digital health solutions.
What's next for Syllable?
With the successful closure of its latest financing round, Syllable is well-positioned to accelerate its product roadmap and expand its market footprint. The company is expected to prioritize the scaling of its AI-powered communication tools, potentially integrating deeper analytics and predictive capabilities to further optimize hospital workflows. As the healthcare industry continues to embrace digital transformation, Syllable's strategic focus will likely remain on enhancing the interoperability of its solutions with existing electronic health record systems. This capital injection provides the necessary runway to bolster engineering talent and pursue aggressive customer acquisition strategies, ensuring the firm remains at the forefront of the healthcare technology innovation cycle.
See full Syllable company page
